Published in Drug Law Weekly, July 15th, 2008
"The mechanisms responsible for the elevated IGFBP-I levels in these conditions are still unclear. Interestingly, high levels of vasopressin have been reported in the above-mentioned conditions. To study the effect of vasopressin on IGFBP-1. in humans. Placebo-con trolled cross-over study in patients with central diabetes insipidus (CDI) in whom potential interference from endogenous vasopressin secretion is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.